Repligen Corporation Set to Join the S&P SmallCap 600
S&P SmallCap 600 constituent Akorn Inc. is acquiring Hi-Tech Pharmacal Co. in a deal expected to be completed soon.
Small Cap Stocks to Watch: The Future of Diabetes Care
April 15, 2014 An article this month from Reuters Health involved a positive message for Americans at-risk for diabetes or suffering from the disease: out-of-pocket expenses for diabetes treatment has actually decreased, according to a study just released by the CDC.
View Press Release
The unanimous vote in support of the transactions follows Akorn's agreement to a proposed consent order requiring divestiture of certain products as a condition to obtaining FTC approval.
UPDATE 1-Akorn gets U.S. approval to buy Hi-Tech Pharmacal, with conditions
Generic drugmaker Akorn Enterprises Inc has won U.S. antitrust approval to buy rival Hi-Tech Pharmacal Inc on condition that it sell three generic prescription eye medications and two generic topical anesthetics, the Federal Trade Commission said on Monday.